Dexamethasone eye drops 0.1%, 5 ml

Use in adults, including elderly patients: in the presence of acute inflammation, Dexamethasone should be instilled 1 drop into the conjunctival sac in 1-2 hours, after improvement of the condition, 1 drop every 4-6 hours.

For the prevention of inflammatory processes after ophthalmic surgery and injuries: during the first 24 hours after surgery - 1-2 drops 4 times a day, then - 3 times a day for 2 weeks.

The treatment regimen in other cases is 1 drop 3-4 times a day for 2-5 weeks. The decision on the duration of treatment is based on objective data, including the effectiveness of the drug, the severity of symptoms, the possibility of side effects.

The maximum duration of the drug should not exceed 14 days.

Recommendations for the use of bottles with dropper caps: before using the drug, remove the aluminum cap from the bottle, remove the rubber stopper and close the bottle with a dropper cap, previously released from the packaging. Then remove the cap from the dropper cap, turn the bottle over, drip the required number of drops of the drug. After use, return the bottle to an upright position and put the cap on the dropper cap.

Recommendations for the use of a dropper tube (t / c): remove the protective cap, cut off the membrane of the body neck with scissors, without damaging the threaded part. Turn the hot / cold body with the drug with the neck down and gently press the hot / cold body, using it like a pipette. After using the dose recommended as prescribed by the doctor or the dose specified in the instructions for use of the medicinal product, turn the hot-case housing with the threaded part upwards and screw on the protective cap.

For 1 ml:

active substance: dexamethasone sodium phosphate (in terms of anhydrous and alcohol-free dexamethasone sodium phosphate) - 1 mg;

auxiliary substances: boric acid - 15 mg, sodium tetraborate decahydrate - 0.6 mg, disodium edetate dihydrate - 0.5 mg, benzalkonium chloride - 0.04 mg, water for injection - up to 1 ml.

• Bacterial, viral, fungal eye diseases,

• tuberculous lesion of the eyes,

• violation of the integrity of the ocular epithelium,

• an acute form of purulent eye infection in the absence of specific therapy,

• corneal diseases associated with epithelial defects, trachoma, glaucoma.

Pharmacodynamics

Dexamethasone is a synthetic fluorinated glucocorticosteroid that has no mineralocorticoid activity. It has a pronounced anti-inflammatory, anti-allergic and desensitizing effect. Dexamethasone actively suppresses inflammatory processes, inhibiting the release of inflammatory mediators by eosinophils, migration of mast cells and reducing capillary permeability, vasodilation.

Pharmokinetics

When applied topically, it penetrates well into the epithelium of the cornea and the conjunctiva: therapeutic concentrations are achieved in the aqueous humor of the eye; with inflammation or damage to the mucous membrane, the rate of penetration increases.

Overdose

In case of contact with the eyes of an excessive amount of the drug, it is recommended to rinse the eyes with warm water. No toxic effects are expected in case of overdose with topical application or if the contents of one vial are accidentally swallowed. Overdose symptoms may be local manifestations.

Treatment for overdose is symptomatic.

Side effects

The following adverse reactions have been reported in clinical trials:

Nervous system disorders: infrequently: dysgeusia.

Disturbances from the organ of vision: often: discomfort in the eyes. Uncommon: keratitis, conjunctivitis, 'dry' keratoconjunctivitis, corneal staining, photophobia, blurred vision, itching in the eye, foreign body sensation in the eyes, increased tearing, unusual sensations in the eye, crusting at the edges of the eyelids, eye irritation, redness of the eyes.

Adverse reactions, the frequency of which has not been established (post-marketing experience):

Immune system disorders: hypersensitivity.

Nervous system disorders: dizziness, headache.

Violations of the organ of vision: increased intraocular pressure, decreased visual acuity, corneal erosion, eyelid ptosis, eye pain, mydriasis.

It has been reported about very rare cases of the development of corneal calcification with previous significant damage due to the presence of phosphates in the preparation.

Drug interactions

Concomitant use of topical steroids and topical non-steroidal anti-inflammatory drugs may increase the likelihood of impaired corneal healing.

The risk of an additional increase in intraocular pressure cannot be excluded if dexamethasone is used in conjunction with anticholinergics, which can also cause an increase in intraocular pressure in predisposed patients. In the case of combined use with antiglaucoma drugs, it is possible to reduce the hypotensive effect of the latter.

In the case of use with other topical ophthalmic drugs, the interval between their use should be at least 10 minutes.

Eye ointments should be used last.